Investors Face September Deadline in Capricor Therapeutics Lawsuit

The legal action follows a sharp decline in Capricor’s market value after the U.S. Food and Drug Administration released briefing documents on July 27, 2026. These documents revealed that the company altered its statistical analysis plan without prior FDA review or agreement. Regulators determined these post-study changes were exploratory and lacked scientific justification, ultimately casting doubt on the effectiveness of Deramiocel.

Following the disclosure, Capricor’s stock plummeted 64%, closing at $7.00 per share. The lawsuit, Nkamga v. Capricor Therapeutics, Inc., et al., contends that executives failed to disclose material information in violation of federal securities laws. Investors seeking to participate or discuss their legal options may contact the firm Kahn Swick & Foti, LLC, which is overseeing the case.